v3.26.1
Stockholders’ Deficit (Tables)
 6 Months Ended
Jul. 31, 2026
Equity [Abstract]  
Schedule of Reserved Shares of Common Stock
The Company has reserved shares of its common stock for future issuance as follows (in thousands):
July 31,January 31,
20262026
2014 Stock Option and Grant Plan:
Outstanding stock options8,657 8,970 
Outstanding restricted stock units5,094 9,227 
2024 Equity Incentive Plan:
Outstanding restricted stock units16,583 12,294 
Shares available for future issuance under the 2024 Plan64,254 58,406 
2024 Employee Stock Purchase Plan6,571 5,090 
Total shares of common stock reserved101,159 93,987 
Schedule of Stock Options Roll Forward
A summary of the stock option activity and related information is as follows:
Number of
Options		Weighted-
Average
Exercise Price		Weighted-
Average
Remaining
Contractual
Term (years)		Aggregate
Intrinsic
Value (in
thousands)
Outstanding as of January 31, 20268,970,353 $29.20 7.6$239,954 
Granted— — — — 
Exercised(312,727)4.85 — 19,123 
Cancelled(500)7.99 — — 
Outstanding as of July 31, 20268,657,126 $30.08 7.3$366,013 
Vested and exercisable as of July 31, 20263,656,764 $27.46 6.7$164,195 
Schedule of Nonvested Restricted Stock Units Activity
A summary of the RSU activity and related information is as follows:
Number of
RSUs		Weighted-Average
Grant Date Fair Value
Unvested as of January 31, 202621,480,571 $48.73 
Granted8,176,890 53.27 
Vested(4,908,637)40.32 
Forfeited(3,071,333)45.65 
Outstanding as of July 31, 202621,677,491 $52.79 
Schedule of the Assumptions Used in Estimating Fair Value of ESPP
The Company estimated the fair value of ESPP purchase rights using a Black-Scholes option-pricing model with the following assumptions:
Three and Six Months Ended July 31,
20262025
Expected term (in years)
0.5 - 2.0
0.5 - 2.0
Expected volatility
59.4% - 61.2%
59.0% - 64.7%
Risk-free interest rate
3.8% - 3.8%
3.9% - 4.3%
Dividend yield——
Schedule of Stock-Based Compensation Expense
Total stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of operations was as follows (in thousands):
Three Months Ended July 31,Six Months Ended July 31,
2026202520262025
Cost of revenue
Subscription$5,576 $4,143 $10,207 $8,111 
Other921 708 1,555 1,565 
Research and development36,578 24,734 69,604 44,546 
Sales and marketing36,857 29,638 53,188 53,782 
General and administrative21,086 29,234 39,832 53,993 
Total stock-based compensation expense$101,018 $88,457 $174,386 $161,997